UPKAR BADHESHA: Open Payments
NPI 1285171751 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,361 in 51 payments from 13 companies in 2025. Trend: 2023 $127 · 2024 $574 · 2025 $1,361
Food & beverage: $1,227Education: $134
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $309 |
| Incyte Corporation | 6 | $188 |
| CSL Behring | 5 | $184 |
| GlaxoSmithKline, LLC. | 16 | $165 |
| Regeneron Healthcare Solutions, Inc. | 8 | $164 |
| SANOFI-AVENTIS U.S. LLC | 1 | $100 |
| BioCryst US Sales Co., LLC | 3 | $79 |
| Amgen Inc. | 3 | $66 |
| GENZYME CORPORATION | 1 | $27 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
Products named: DUPIXENT, OPZELURA, Andembry, TRELEGY ELLIPTA, TEZSPIRE, FASENRA, ORLADEYO, AIRSUPRA.
Industry payments across CA — which companies pay providers there.
